Company News: Page (1) of 1 - 06/15/12 Email this story to a friend. email article Print this page (Article printing at page facebook

Undervalued Biotech with a Strong Pipeline; Special Report by Leading Financial Web Site Penny Stock Detectives

  (June 15, 2012)

New York, NY (PRWEB) June 15, 2012

In a recent Penny Stock Detectives article, editor Sasha Cekerevac argues that monoclonal antibody-based therapies are the next great investment opportunity in the biotech sector. Cekerevac believes XOMA is one company that will soon introduce new antibody-based therapies.

XOMAs main product is called gevokizumab (XOMA 052). This antibody is designed to treat inflammation, which has been shown to cause multiple diseases.

A lot of recent research shows that by controlling and reducing inflammation, many diseases can also be treated successfully, notes Cekerevac. Considering the poor health of many Americans, this potential profit center is generating a lot of interest from numerous biotech companies.

According to the Penny Stock Detectives article, one of the biggest issues with biotech companies is whether or not their drugs can get approved by the U.S. Food and Drug Administration (FDA). This is not an easy process, and it normally involves three phases. Biotech companies can have significant stumbling blocks in any one of these phases.

XOMAs gevokizumab product has passed phase one and two; the company is now looking at phase-three development. The company is also working on the development of more drugs, many of which are showing promise and could be potentially significant additions to the firms revenue stream.

Biotech companies need a strong fundamental story, and Cekerevac believes XOMA has just that.

I think that, following the recent good news, many investors interested in XOMA are waiting for more information regarding further testing and the development of phase three, says Cekerevac. This is one I would keep a close eye on.

To see the full article and to learn more about Penny Stock Detectives, visit

The editors of Penny Stock Detectives believe low-priced stocks, when researched properly, present investors with great opportunities to accumulate wealth and to increase the value of their investment portfolios. You can learn more about Penny Stock Detectives at

Sasha Cekerevac, BA, and Danny Esposito, B. Comm., lead editorial stock analysts at Penny Stock Detectives, in conjunction with stock market guru George Leong, B. Comm., have just updated their breakthrough video, If You Missed Apple, Shame on Us; If You Miss Thiswhich highlights a company these stock analysts believe looks very similar to Apple Inc. in its early days. To see the video, visit:

Read the full story at

Page: 1

Related Keywords:restraint of trade,international (foreign) trade,trade dispute,trade agreements,trade policy,trade balance,economy, business and finance,financial and business service,,business enterprises,business (general),economy, business and finance,financial and business service,investment service,business enterprises,business (general),fishing industry,cinema industry,radio industry,television industry,music industry,process industry,economy, business and finance,banking,personal investing,personal service,,personal income,


Our Privacy Policy --- @ Copyright, 2015 Digital Media Online, All Rights Reserved